Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

Dongweon Song, Raghothama Chaerkady, Aik-Choon Tan, Elena García-García, Anuradha Nalli, Ana Suárez-Gauthier, Fernando López-Ríos, Feng Zhang Xian, Anna Solomon, Jeffrey Tong, Margaret Read, Christian Fritz, Antonio Jimeno, Akhilesh Pandey, Manuel Hidalgo

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Targeting Hsp90 is an attractive strategy for anticancer therapy because the diversity and relevance of biological processes are regulated by these proteins in most cancers. However, the role and mode of action of Hsp90 inhibitors in pancreatic cancer has not been studied. This study aimed to assess the antitumor activity of the Hsp90 inhibitor, IPI-504, in pancreatic cancer and to determine the biological effects of the agent. In vitro, we show that pharmacologic inhibition of Hsp90 by IPI-504 exerts antiproliferative effects in a panel of pancreatic cancer cells in a dose- and time-dependent manner. In pancreatic cancer xenografts obtained directly from patients with pancreas cancer, the agent resulted in a marked suppression of tumor growth. Although known Hsp90 client proteins were significantly modulated in IPI-504-treated cell line, no consistent alteration of these proteins was observed in vivo other than induction of Hsp70 expression in the treated xenografted tumors. Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. The majority of these proteins belong to the functional class of intracellular signal transduction, immune response, cell growth and maintenance, transport, and metabolism. In summary, we show that IPI-504 has potent antitumor activity in pancreatic cancer and identify potential pharmacologic targets using a proteomics and gene expression profiling.

Original languageEnglish
Pages (from-to)3275-3284
Number of pages10
JournalMolecular Cancer Therapeutics
Volume7
Issue number10
DOIs
Publication statusPublished - 2008 Oct 1
Externally publishedYes

Fingerprint

tanespimycin
HSP90 Heat-Shock Proteins
Pancreatic Neoplasms
Proteins
Proteomics
Neoplasms
Growth
Galectin 3
Biological Phenomena
HLA-B Antigens
Glycosylated Hemoglobin A
Biological Factors
Gene Expression Profiling
Heterografts
Isotopes
Signal Transduction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Song, D., Chaerkady, R., Tan, A-C., García-García, E., Nalli, A., Suárez-Gauthier, A., ... Hidalgo, M. (2008). Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Molecular Cancer Therapeutics, 7(10), 3275-3284. https://doi.org/10.1158/1535-7163.MCT-08-0508

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. / Song, Dongweon; Chaerkady, Raghothama; Tan, Aik-Choon; García-García, Elena; Nalli, Anuradha; Suárez-Gauthier, Ana; López-Ríos, Fernando; Xian, Feng Zhang; Solomon, Anna; Tong, Jeffrey; Read, Margaret; Fritz, Christian; Jimeno, Antonio; Pandey, Akhilesh; Hidalgo, Manuel.

In: Molecular Cancer Therapeutics, Vol. 7, No. 10, 01.10.2008, p. 3275-3284.

Research output: Contribution to journalArticle

Song, D, Chaerkady, R, Tan, A-C, García-García, E, Nalli, A, Suárez-Gauthier, A, López-Ríos, F, Xian, FZ, Solomon, A, Tong, J, Read, M, Fritz, C, Jimeno, A, Pandey, A & Hidalgo, M 2008, 'Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer', Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3275-3284. https://doi.org/10.1158/1535-7163.MCT-08-0508
Song, Dongweon ; Chaerkady, Raghothama ; Tan, Aik-Choon ; García-García, Elena ; Nalli, Anuradha ; Suárez-Gauthier, Ana ; López-Ríos, Fernando ; Xian, Feng Zhang ; Solomon, Anna ; Tong, Jeffrey ; Read, Margaret ; Fritz, Christian ; Jimeno, Antonio ; Pandey, Akhilesh ; Hidalgo, Manuel. / Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 10. pp. 3275-3284.
@article{0a8289db8d444340930a3f1ca1cfbeac,
title = "Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer",
abstract = "Targeting Hsp90 is an attractive strategy for anticancer therapy because the diversity and relevance of biological processes are regulated by these proteins in most cancers. However, the role and mode of action of Hsp90 inhibitors in pancreatic cancer has not been studied. This study aimed to assess the antitumor activity of the Hsp90 inhibitor, IPI-504, in pancreatic cancer and to determine the biological effects of the agent. In vitro, we show that pharmacologic inhibition of Hsp90 by IPI-504 exerts antiproliferative effects in a panel of pancreatic cancer cells in a dose- and time-dependent manner. In pancreatic cancer xenografts obtained directly from patients with pancreas cancer, the agent resulted in a marked suppression of tumor growth. Although known Hsp90 client proteins were significantly modulated in IPI-504-treated cell line, no consistent alteration of these proteins was observed in vivo other than induction of Hsp70 expression in the treated xenografted tumors. Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. The majority of these proteins belong to the functional class of intracellular signal transduction, immune response, cell growth and maintenance, transport, and metabolism. In summary, we show that IPI-504 has potent antitumor activity in pancreatic cancer and identify potential pharmacologic targets using a proteomics and gene expression profiling.",
author = "Dongweon Song and Raghothama Chaerkady and Aik-Choon Tan and Elena Garc{\'i}a-Garc{\'i}a and Anuradha Nalli and Ana Su{\'a}rez-Gauthier and Fernando L{\'o}pez-R{\'i}os and Xian, {Feng Zhang} and Anna Solomon and Jeffrey Tong and Margaret Read and Christian Fritz and Antonio Jimeno and Akhilesh Pandey and Manuel Hidalgo",
year = "2008",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0508",
language = "English",
volume = "7",
pages = "3275--3284",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

AU - Song, Dongweon

AU - Chaerkady, Raghothama

AU - Tan, Aik-Choon

AU - García-García, Elena

AU - Nalli, Anuradha

AU - Suárez-Gauthier, Ana

AU - López-Ríos, Fernando

AU - Xian, Feng Zhang

AU - Solomon, Anna

AU - Tong, Jeffrey

AU - Read, Margaret

AU - Fritz, Christian

AU - Jimeno, Antonio

AU - Pandey, Akhilesh

AU - Hidalgo, Manuel

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Targeting Hsp90 is an attractive strategy for anticancer therapy because the diversity and relevance of biological processes are regulated by these proteins in most cancers. However, the role and mode of action of Hsp90 inhibitors in pancreatic cancer has not been studied. This study aimed to assess the antitumor activity of the Hsp90 inhibitor, IPI-504, in pancreatic cancer and to determine the biological effects of the agent. In vitro, we show that pharmacologic inhibition of Hsp90 by IPI-504 exerts antiproliferative effects in a panel of pancreatic cancer cells in a dose- and time-dependent manner. In pancreatic cancer xenografts obtained directly from patients with pancreas cancer, the agent resulted in a marked suppression of tumor growth. Although known Hsp90 client proteins were significantly modulated in IPI-504-treated cell line, no consistent alteration of these proteins was observed in vivo other than induction of Hsp70 expression in the treated xenografted tumors. Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. The majority of these proteins belong to the functional class of intracellular signal transduction, immune response, cell growth and maintenance, transport, and metabolism. In summary, we show that IPI-504 has potent antitumor activity in pancreatic cancer and identify potential pharmacologic targets using a proteomics and gene expression profiling.

AB - Targeting Hsp90 is an attractive strategy for anticancer therapy because the diversity and relevance of biological processes are regulated by these proteins in most cancers. However, the role and mode of action of Hsp90 inhibitors in pancreatic cancer has not been studied. This study aimed to assess the antitumor activity of the Hsp90 inhibitor, IPI-504, in pancreatic cancer and to determine the biological effects of the agent. In vitro, we show that pharmacologic inhibition of Hsp90 by IPI-504 exerts antiproliferative effects in a panel of pancreatic cancer cells in a dose- and time-dependent manner. In pancreatic cancer xenografts obtained directly from patients with pancreas cancer, the agent resulted in a marked suppression of tumor growth. Although known Hsp90 client proteins were significantly modulated in IPI-504-treated cell line, no consistent alteration of these proteins was observed in vivo other than induction of Hsp70 expression in the treated xenografted tumors. Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. The majority of these proteins belong to the functional class of intracellular signal transduction, immune response, cell growth and maintenance, transport, and metabolism. In summary, we show that IPI-504 has potent antitumor activity in pancreatic cancer and identify potential pharmacologic targets using a proteomics and gene expression profiling.

UR - http://www.scopus.com/inward/record.url?scp=55749110744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749110744&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0508

DO - 10.1158/1535-7163.MCT-08-0508

M3 - Article

C2 - 18852131

AN - SCOPUS:55749110744

VL - 7

SP - 3275

EP - 3284

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -